NCT06335914Recruiting
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 21 Mar 2024
- Start date
- 3 Apr 2025
- Primary completion date
- 4 Mar 2029
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Prostate cancer
- NCT number
- NCT06335914
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 3 Apr 2025 to the primary completion date, 4 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Under a randomized-controlled trial with unknown allocation of systemic therapy
- Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
- another active malignancy
- patient on dialysis
- another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging
Other illness
- conditions which would significantly impair the patient's ability to comply with study procedures and follow up
Other
- Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
- Unable to provide written consent by patient and their legal representatives
- In the opinion of the treating physician:
Who the study is looking for
- Male, age ≥ 18 years
- Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
- Poor risk patients with mCSPC at study enrollment
- De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
- High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
- Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
- No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
- Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.